share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Jordt Raymond M

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Jordt Raymond M

Altimmune | 4：持股变动声明-高管 Jordt Raymond M
美股sec公告 ·  08/01 17:46
Moomoo AI 已提取核心信息
Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 917 shares of common stock on July 31, 2024. The transaction was carried out directly with the shares valued at $5.41 each. Following this acquisition, Jordt's total direct holdings in the company increased to 14,660 shares. The transaction is part of a grant, award, or other acquisition, as per the transaction code description provided.
Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 917 shares of common stock on July 31, 2024. The transaction was carried out directly with the shares valued at $5.41 each. Following this acquisition, Jordt's total direct holdings in the company increased to 14,660 shares. The transaction is part of a grant, award, or other acquisition, as per the transaction code description provided.
2024年7月31日，Altimmune首席业务官Raymond M. Jordt直接购买了917股普通股，并以每股5.41美元的价格成交。此次收购后，Jordt在公司的直接持股总数增加至14,660股。根据交易代码说明，此次交易是一项授予、奖励或其他收购。
2024年7月31日，Altimmune首席业务官Raymond M. Jordt直接购买了917股普通股，并以每股5.41美元的价格成交。此次收购后，Jordt在公司的直接持股总数增加至14,660股。根据交易代码说明，此次交易是一项授予、奖励或其他收购。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息